GI Innovation partners with MSD for clinical trials combining immunotherapy agents

SEOUL, August 26 (AJU PRESS) - Korea's pharmaceutical company GI Innovation announced Monday it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with American multinational pharmaceutical firm Merck & Co.

Under the agreement, the two companies will evaluate the efficacy of combining GI Innovation's immunotherapy agent GI-102 with MSD's immunotherapy drug Keytruda in clinical trials involving patients with resistant liver cancer, melanoma, and kidney cancer.

GI-102 is described by GI Innovation as a therapeutic agent with the ability to increase the number of immune cells by an average of five times, demonstrating potent immune cell proliferation capabilities.

Kim Joo-heon jhkim123@ajunews.com

GI Innovation partners with MSD for clinical trials combining immunotherapy agents

Related